Cisplatin given at three divided doses for three consecutive days in metastatic breast cancer: an alternative schedule for one full dose with comparable efficacy but less CINV and hypomagnesaemia-Reference-Cited by-同舟云学术

Cisplatin given at three divided doses for three consecutive days in metastatic breast cancer: an alternative schedule for one full dose with comparable efficacy but less CINV and hypomagnesaemia

Published:2020-06-10 Issue:3 Volume:182 Page:719-726
ISSN:0167-6806
Container-title:Breast Cancer Research and Treatment
language:en
Short-container-title:Breast Cancer Res Treat

Author:

Zhang Jinfeng,Lin Mingxi,Jin Yizi,Gu Linhan,Li Ting,Yuan Baoying,Wang Biyun,Wang Leiping,Zhang Sheng,Cao Jun,Tao Zhonghua,Zhang Jian^ORCID,Hu Xichun

Funder

Science and Technology Commission of Shanghai Municipality

Shanghai Municipal Population and Family Planning Commission

Natural Science Foundation of Shanghai

Damon Runyon Cancer Research Foundation

Shanghai Hospital Development Center

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology

Link

https://link.springer.com/content/pdf/10.1007/s10549-020-05730-2.pdf

Reference41 articles.

1. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A (2015) Global cancer statistics, 2012. CA: A Cancer J Clin 65(2):87–108. https://doi.org/10.3322/caac.21262

2. Kamby C, Vejborg I, Kristensen B, Olsen LO, Mouridsen HT (1988) Metastatic pattern in recurrent breast cancer special reference to intrathoracic recurrences. Cancer 62(10):2226–2233. https://doi.org/10.1002/1097-0142(19881115)62:10<2226:aid-cncr2820621026>3.0.co;2-d

3. Sun S, Tang L, Zhang J, Lv F, Wang Z, Wang L, Zhang Q, Zheng C, Qiu L, Jia Z, Lu Y, Liu G, Shao Z, Wang B, Hu X (2014) Cisplatin improves antitumor activity of weekly nab-paclitaxel in patients with metastatic breast cancer. Int J Nanomed 9:1443–1452. https://doi.org/10.2147/ijn.S58275

4. Heinemann V (2002) Gemcitabine plus cisplatin for the treatment of metastatic breast cancer. Clinical Breast Cancer 3(Suppl 1):24–29. https://doi.org/10.3816/cbc.2002.s.006

5. Zhang J, Wang Z, Hu X, Wang B, Wang L, Yang W, Liu Y, Liu G, Di G, Hu Z, Wu J, Shao Z (2015) Cisplatin and gemcitabine as the first line therapy in metastatic triple negative breast cancer. Int J Cancer 136(1):204–211. https://doi.org/10.1002/ijc.28966

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Split-Dose Cisplatin in Patients With Locally Advanced or Metastatic Urothelial Carcinoma: A Systematic Literature Review and Network Meta-Analysis;Clinical Genitourinary Cancer;2024-12

2. Two doses of fosaprepitant included prophylactic treatment for the three-day cisplatin-based chemotherapy induced nausea and vomiting;Journal of Cancer Research and Clinical Oncology;2024-06-05

3. Advancing perspectives on the off-label use of anticancer drugs: an updated classification and exploration of categories;Frontiers in Pharmacology;2024-06-04

4. A multicenter, randomized, double-blind, placebo-controlled, phase 3 trial of olanzapine plus triple antiemetic regimen for the prevention of multiday highly emetogenic chemotherapy-induced nausea and vomiting (OFFER study);eClinicalMedicine;2023-01

5. CACA Guidelines for Holistic Integrative Management of Breast Cancer;Holistic Integrative Oncology;2022-07-05